Alexander J Lepak

List of Publications by Year
in descending order

39 papers	938 citations	471509 17 h-index	454955 30 g-index
40 all docs	40 docs citations	40 times ranked	1289 citing authors

#	Article	IF	Citations
1	Implementation of infection control measures to prevent healthcare-associated transmission of severe acute respiratory coronavirus virus 2 (SARS-CoV-2). Infection Control and Hospital Epidemiology, 2021, 42, 229-232.	1.8	8
2	Viral Sequencing to Investigate Sources of SARS-CoV-2 Infection in US Healthcare Personnel. Clinical Infectious Diseases, 2021, 73, e1329-e1336.	5.8	43
3	Implementation of telehealth antimicrobial stewardship through partnership of an academic medical center and a community hospital. American Journal of Health-System Pharmacy, 2021, 78, 2256-2264.	1.0	4
4	Association of Changes in Seasonal Respiratory Virus Activity and Ambulatory Antibiotic Prescriptions With the COVID-19 Pandemic. JAMA Internal Medicine, 2021, 181, 1399.	5.1	19
5	Reply to Maziade et al. Clinical Infectious Diseases, 2021, 73, 1548.	5.8	0
6	COVID-19 in Health Care Personnel. Mayo Clinic Proceedings, 2021, 96, 2312-2322.	3.0	8
7	Clinical utility of dual anterior nares and oropharynx MRSA screening polymerase chian reaction assay (PCR) for patients with suspected pneumonia. Infection Control and Hospital Epidemiology, 2021, , 1-3.	1.8	1
8	Clinical Utility of Dual Anterior Nares and Oropharynx MRSA Screening PCR for Patients with Suspected Pneumonia â€“ ERRATUM. Infection Control and Hospital Epidemiology, 2021, , 1-1.	1.8	0
9	In Vivo Pharmacodynamic Evaluation of Omadacycline against Staphylococcus aureus in the Neutropenic Mouse Pneumonia Model. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	8
10	Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube. Journal of Antimicrobial Chemotherapy, 2020, 75, 3023-3028.	3.0	13
11	FDA Public Workshop Summary: Advancing Animal Models for Antibacterial Drug Development. Antimicrobial Agents and Chemotherapy, 2020, 65, .	3.2	11
12	Pharmacodynamic Evaluation of MRX-8, a Novel Polymyxin, in the Neutropenic Mouse Thigh and Lung Infection Models against Gram-Negative Pathogens. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	24
13	Utility of Repeat Nasopharyngeal SARS-CoV-2 RT-PCR Testing and Refinement of Diagnostic Stewardship Strategies at a Tertiary Care Academic Center in a Low-Prevalence Area of the United States. Open Forum Infectious Diseases, 2020, 7, ofaa388.	0.9	3
14	In Vivo Pharmacodynamic Target Determination for Delafloxacin against Klebsiella pneumoniae and Pseudomonas aeruginosa in the Neutropenic Murine Pneumonia Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	9
15	Determination of Pharmacodynamic Target Exposures for Rezafungin against Candida tropicalis and Candida dubliniensis in the Neutropenic Mouse Disseminated Candidiasis Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	16
16	APX001 Pharmacokinetic/Pharmacodynamic Target Determination against Aspergillus fumigatus in an In Vivo Model of Invasive Pulmonary Aspergillosis. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	37
17	In Vivo Pharmacodynamics of Omadacycline against Staphylococcus aureus in the Neutropenic Murine Thigh Infection Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	26
18	WCK 5222 (Cefepime-Zidebactam) Pharmacodynamic Target Analysis against Metallo-Î²-Lactamase-Producing Enterobacteriaceae in the Neutropenic Mouse Pneumonia Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	17

#	Article	IF	Citations
19	Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	15
20	In vitro evaluation of meropenem-vaborbactam against clinical CRE isolates at a tertiary care center with low KPC-mediated carbapenem resistance. Diagnostic Microbiology and Infectious Disease, 2019, 93, 258-260.	1.8	10
21	In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	56
22	The Wrong Frame of Mind. New England Journal of Medicine, 2018, 378, 1716-1721.	27.0	2
23	1389. Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model Against S. aureus (SA) and S. pneumoniae (SPN). Open Forum Infectious Diseases, 2018, 5, S426-S426.	0.9	1
24	Pharmacodynamic Evaluation of Rezafungin (CD101) against Candida auris in the Neutropenic Mouse Invasive Candidiasis Model. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	56
25	In Vivo Pharmacodynamic Characterization of a Novel Odilorhabdin Antibiotic, NOSO-502, against Escherichia coli and Klebsiella pneumoniae in a Murine Thigh Infection Model. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	9
26	Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	48
27	In Vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	37
28	In Vivo Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	71
29	In Vivo Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	35
30	Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	22
31	Pharmacodynamic Optimization for the Treatment of Invasive Candida auris Infection. Open Forum Infectious Diseases, 2017, 4, S73-S73.	0.9	1
32	Isavuconazole: Has It Saved Us? A Pharmacotherapy Review and Update on Clinical Experience. Current Treatment Options in Infectious Diseases, 2017, 9, 356-370.	1.9	1
33	Pharmacodynamic Optimization for Treatment of Invasive Candida auris Infection. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	65
34	Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses for Delafloxacin to Provide Dose Selection Support for the Treatment of Patients With Community-Acquired Bacterial Pneumonia (CABP). Open Forum Infectious Diseases, 2016, 3, .	0.9	1
35	Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents. Bioorganic and Medicinal Chemistry, 2016, 24, 6390-6400.	3.0	79
36	In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model. Antimicrobial Agents and Chemotherapy, 2016, 60, 4764-4769.	3.2	44

#	Article	IF	Citations
37	Pharmacodynamic Target Evaluation of a Novel Oral Glucan Synthase Inhibitor, SCY-078 (MK-3118), Using an In Vivo Murine Invasive Candidiasis Model. Antimicrobial Agents and Chemotherapy, 2015, 59, 1265-1272.	3.2	83
38	In Vivo Pharmacokinetics and Pharmacodynamics of the Lantibiotic NAI-107 in a Neutropenic Murine Thigh Infection Model. Antimicrobial Agents and Chemotherapy, 2015, 59, 1258-1264.	3.2	32
39	Antifungal PK/PD Considerations in Fungal Pulmonary Infections. Seminars in Respiratory and Critical Care Medicine, 2011, 32, 783-794.	2.1	22